FDA, NanoKnife

NanoKnife gains FDA clearance for prostate tissue ablation
AngioDynamics has won US Food and Drug Administration (FDA) clearance for its NanoKnife system to be used in prostate cancer patients. The system, which was already FDA-cleared for the surgical ablation of soft tissue,
AngioDynamics wins FDA clearance for NanoKnife system in prostate tissue ablation
AngioDynamics received FDA 510(k) clearance for its NanoKnife system for prostate tissue ablation in intermediate-risk prostate cancer.
FDA clears AngioDynamics’ NanoKnife pulsed field ablation system for prostate cancer
AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target and destroy tissue without delivering excess heat and the uni | AngioDynamics obtained a green light for its NanoKnife prostate cancer ablation system,
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife
AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for prostate tissue ablation. The clearance for the NanoKnife System for prostate tissue ablation follows the completion of the pivotal PRESERVE clinical study and submission of results to the FDA in September.
AngioDynamics Shares at 52-Week High After FDA Clears NanoKnife
Shares of AngioDynamics hit a 52-week high after the company's NanoKnife System for prostate tissue ablation received regulatory clearance. The stock jumped almost 35% to a high of $9.42 in early trading. Shares are now in positive territory year-to-date.
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life,
AngioDynamics receives FDA 510(k) clearance for NanoKnife System
AngioDynamics (ANGO) announced it received U.S. FDA 510(k) clearance for the NanoKnife System for prostate tissue ablation. Pick the best
Science Daily1d
Study finds new blood test predicts prognosis for advanced prostate cancer patients
A new study found that a DNA sequencing test for advanced prostate cancer patients can distinguish between patients with poor and favorable prognoses.
DNA sequencing test can predict prognosis for advanced prostate cancer patients
Published in Nature Communications, a new study led by the University of Minnesota Medical School and Duke University found ...
BioPharma Dive10d
Janux impresses Wall Street with new prostate cancer drug results
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to ...
Business Wire16h
PanGIA Biotech Announces Landmark Partnership Agreement for First Liquid Biopsy Prostate Cancer Assay in India
PanGIA Biotech–a pioneer in liquid biopsy technology–today announced its first international partnership, collaborating with Canary Oncoceutics (Canar ...